MBIO — MindBio Therapeutics Cashflow Statement
0.000.00%
- CA$5.40m
- CA$9.74m
Annual cashflow statement for MindBio Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Net Income/Starting Line | -0.477 | -7.51 | -4.29 |
Non-Cash Items | 0 | 1.96 | 2.48 |
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | 0.477 | 0.823 | -0.405 |
Change in Accounts Receivable | |||
Change in Payable / Accrued Expenses | |||
Cash from Operating Activities | 0 | -4.72 | -2.21 |
Other Investing Cash Flow Items | 0 | -0.033 | 0 |
Purchase of Investments | |||
Cash from Investing Activities | 0 | -0.033 | 0 |
Financing Cash Flow Items | — | — | -0.108 |
Other Financing Cash Flow | |||
Total Cash Dividends Paid | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 0.48 | 5.59 | 1.04 |
Foreign Exchange Effects | |||
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | 0.48 | 0.835 | -0.996 |